Dietary inorganic nitrate: From villain to hero in metabolic disease?

Ben McNally¹,², Julian L. Griffin¹,² and Lee D. Roberts¹,²

1 Elsie Widdowson Laboratory, Medical Research Council – Human Nutrition Research, Cambridge, UK
2 Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK

Historically, inorganic nitrate was believed to be an inert by-product of nitric oxide (NO) metabolism that was readily excreted by the body. Studies utilising doses of nitrate far in excess of dietary and physiological sources reported potentially toxic and carcinogenic effects of the anion. However, nitrate is a significant component of our diets, with the majority of the anion coming from green leafy vegetables, which have been consistently shown to offer protection against obesity, type 2 diabetes and metabolic diseases. The discovery of a metabolic pathway in mammals, in which nitrate is reduced to NO, via nitrite, has warranted a re-examination of the physiological role of this small molecule. Obesity, type 2 diabetes and the metabolic syndrome are associated with a decrease in NO bioavailability. Recent research suggests that the nitrate-nitrite-NO pathway may be harnessed as a therapeutic to supplement circulating NO concentrations, with both anti-obesity and anti-diabetic effects, as well as improving vascular function. In this review, we examine the key studies that have led to the re-evaluation of the physiological function of inorganic nitrate, from toxic and carcinogenic metabolite, to a potentially important and beneficial agent in the treatment of metabolic disease.

Keywords:
Adipose Tissue / Diabetes / Dietary inorganic nitrate / Metabolism / Metabolic disease / Nitric oxide / Obesity

1 Introduction

Until recently dietary inorganic nitrate was thought to be hazardous to human health. In 2006, the International Agency for Research on Cancer (IARC) concluded that it was probable ingested nitrate was carcinogenic in conditions that promoted endogenous nitrosation [1]. The final report, not published until 2010 [2], highlighted how ingested nitrate and nitrite could trigger carcinogenesis through the formation of deleterious species such as N-nitroso compounds in the presence of nitrosatable compounds. The conclusions of these reports were based on epidemiological studies [3–7], and biochemical theory building on the initial finding that secondary nitrosamines are highly carcinoogenic [8]. However, a recent review has been highly critical of these studies [9], highlighting numerous investigations which do not find an association between nitrate intake and gastric cancers [10–12], as well as confounding issues in the methodology of previous studies which utilised doses of nitrate far in excess of physiological sources.

Nitrate is an important constituent of our diet. Sources of dietary nitrate intake include processed meats, fruits and vegetables. In addition, nitrates and nitrites are often added as a preservative to meats, including sausages, hot dogs and bacon, and were initially suggested to be contributing to the risk to human health posed by preserved and processed meats [13, 14] leading to tight controls on their use. However, of all dietary sources of nitrate it is vegetables that contain the highest concentration, a food group well documented to reduce the risk of obesity and cardiometabolic disease [15–18]. The concentration of nitrate in numerous fruits and vegetables has been well characterised by Hord et al. (Table 1) [19]. Green leafy vegetables, such as celery, spinach, lettuce and rocket, contain the highest nitrate content.

Since the concentration of nitrate and nitrite in vegetables is so much higher than processed meats, it appears unlikely that nitrates and nitrites are the active agents in the risk to health associated with processed meats. In fact, the
World Health Organisation acceptable daily intake for nitrate is 0–3.7 mg/kg. This figure is vastly exceeded (approximately 550%) by a diet relatively rich in fruit and vegetables high in nitrate [19]. Even one portion of spinach can exceed the acceptable daily intake for nitrate. Considering that green leafy vegetables have been consistently shown to offer protection against obesity and cardiometabolic disease in numerous epidemiological studies, the view of nitrate and nitrite must be reassessed. With the identification of an endogenous metabolic pathway catalysing the reduction of nitrate via nitrite to nitric oxide (NO), the nitrate-nitrite-NO pathway [20–22], we have seen a paradigm shift in our understanding of the physiological function of nitrate, in particular with regards to ischaemia-reperfusion injury, stroke, gastric ulceration and, most recently, obesity and aspects of the metabolic syndrome [23, 24].

Here, we discuss the therapeutic potential of inorganic nitrate, as a means of providing bioavailable NO, to treat obesity, diabetes and the metabolic syndrome.

## 2 Nitrate-nitrite-NO pathway

NO is a highly bio-active molecule, signalling via soluble guanylyl cyclase and cyclic guanosine mononucleotide phosphate (cGMP) to bring about a host of physiological functions [25]. Initially, NO was identified as endothelial-derived growth factor, highlighting its role as a potent vasodilator [26, 27]. Further study confirmed fundamental roles for NO/cGMP signalling in the nervous system and the immune system [28–30]. Canonically, NO is synthesised by a family of enzymes termed nitric oxide synthases (NOSs), which consist of three isoforms: neuronal nitric oxide synthase (NOS1), inducible nitric oxide synthase (iNOS, NOS2) and endothelial nitric oxide synthase (eNOS, NOS3) [31]. These enzymes produce NO through the metabolism of L-arginine to L-citrulline [32]. However, a second pathway was subsequently described in vivo identifying the serial reduction of nitrate to nitrite and then to NO [20–22]. This mechanism has been termed the nitrate-nitrite-NO pathway and was initially thought to be purely non-enzymatic. Nitrate from the diet enters the enterosalivary pathway [24] and is then absorbed in the upper gastrointestinal tract entering the blood and raising plasma nitrate levels. A large proportion (approximately 65%) of this nitrate is excreted in the urine [33], but approximately 25% is transported into the salivary glands and concentrated into the saliva (Fig. 1) [22, 34]. Commensal bacteria present in the mouth then use the nitrate as an alternative electron acceptor during respiration, reducing the anion to nitrite [35]. The nitrite in the saliva then enters the acidic environment of the stomach, where it is reduced to NO via a protonated intermediate, nitrous acid [20, 36]. The pathway is enhanced by reducing agents found in the diet, such as vitamin C and polyphenols [37, 38], highlighting the complex interactions between dietary nitrate and additional compounds found as dietary constituents.

Following the description of the non-enzymatic physiological reduction of nitrate through nitrite to NO, work conducted by Jansson et al. identified an enzymatic process functioning to reduce nitrate to NO in mammalian tissue, with xanthine oxidoreductase (XOR) postulated as the enzyme responsible [39]. Previous studies had suggested that mammalian cells and tissues were incapable of reducing nitrate [40], but studies, inspired by the earlier identification of nitrate reductase activity of milk XOR [41], led to the in vitro determination of nitrate reduction by mammalian XOR [42, 43]. Jansson et al. built on this work, demonstrating nitrate reductase activity in a range of rodent and human tissues, which can be inhibited by allopurinol, an inhibitor of XOR [39]. This enzymatic pathway provides an alternative means for the generation of nitrite and NO from dietary nitrate, distinct from the enterosalivary pathway. Jansson et al. also suggested that the enzymatic reduction of nitrate may be as important as the enterosalivary pathway for the production of NO from nitrate, in rodents at least. Plasma nitrite was found to increase in both germ-free and wild-type mice to a similar extent, implying a non-bacterial mechanism of nitrate reduction capable of accounting for the loss of nitrate from enterosalivary pathways. In contrast, however, Govoni et al. demonstrated that the use of an antibacterial mouth wash in humans reduced the concentrations of plasma nitrite, and may reinforce the importance of the enterosalivary pathway. This discrepancy may be due to a lower concentration of nitrate in the saliva of rodents [44]. Currently, the exact contribution of the enterosalivary and enzymatic

| Amount of nitrate (mg/100 g fresh weight) | Food type                                      |
|----------------------------------------|-----------------------------------------------|
| Less than 20                           | Fruits including banana and orange            |
| 20–50                                  | Cured meats including bacon, ham and hot dogs |
| 50–100                                 | Vegetables including onion, pepper, pea, asparagus, mushroom |
| 100–250                                | Vegetables including broccoli, carrot, cauliflower and cucumber. |
| More than 250                          | Vegetables including turnip and cabbage        |
|                                       | Vegetables including leek and fennel          |
|                                       | Vegetables including spinach, lettuce, celery and rocket |

Table adapted from Hord et al. [19].
Figure 1. Dietary nitrate is sequentially reduced to nitrite and then NO via the enterosalivary pathway. Once nitrate is ingested, it is absorbed into the bloodstream in the upper gastrointestinal tract. Here it can mix with nitrite produced by the oxidation of NO and nitrite. This nitrate can then continue along the enterosalivary pathway to be reduced to NO by commensal bacteria in the oral cavity. Further, nitrate could enter cells such as adipocytes (where it may be reduced to NO to bring about systemic changes), or it may be excreted by the kidneys.

Pathways to the reduction of nitrate to NO in vivo remains undefined.

A number of additional physiological sources of nitrate reduction have been identified. Cosby et al. demonstrated that infusions of nitrite into the forearm brachial artery resulted in rapid formation of erythrocyte iron-nitrosylated haemoglobin [45], the NO bound form of haemoglobin. This reaction was inversely proportional to oxyhaemoglobin saturation, highlighting deoxyhaemoglobin as the driver of nitrite reduction to NO. Deoxymyoglobin can also reduce nitrite to NO, at a rate approximately 36 times faster than deoxyhaemoglobin [46]. The deoxymyoglobin-mediated reduction of nitrite to NO has been shown to be important in mitochondrial respiration, cardiac energetics and hypoxic vasodilation [46–48]. Aspects of the mitochondrial respiratory chain have also been implicated in nitrite reduction [49–51]. Nohl et al. used the nitrosylation of deoxyhaemoglobin to follow nitrite reduction to NO by respiring mitochondria. Treatment with mitochondrial complex inhibitors identified ubisemiquinone, as part of the ubiquinone/bc<sub>1</sub> couple (complex III), as essential in the reduction of nitrite to NO by mitochondria [49]. Castello et al. also demonstrated that cytochrome c oxidase (complex IV) could also reduce nitrite to NO in hypoxic conditions [50].

NO has a short half-life (0.05–1.18 ms in human blood), meaning that it can only act locally in an autocrine and paracrine manner to bring about physiological changes [47, 52]. However, the half-lives of both nitrate and nitrite are relatively long in comparison (110 s and 8 h, respectively, in human blood) [52]. Therefore, nitrate and nitrite are more stable and can circulate in the blood, where they may be reduced via the nitrate-nitrite-NO pathway back to NO, and therefore function in an endocrine manner.

While on the surface it appears that the nitrate-nitrite-NO pathway is a redundant mechanism for generating NO, the recycling of nitrate and nitrite in fact provides an important method of producing NO in conditions where NOS enzyme activity is compromised. The NOS enzymes require oxygen to produce NO, therefore NO production via the canonical
Nitrate is known to increase nitric oxide (NO) production through two pathways. The first is the arginine-NO pathway, which is impaired in hypoxic conditions. This pathway involves the conversion of arginine to NO by nitric oxide synthase (NOS). Hypoxia decreases NO production by NOS, leading to impaired vasodilation and impaired insulin signalling in adipose tissue.[24] In contrast, the nitrate-nitrite-NO pathway is capable of reducing nitrate to NO in low oxygen concentrations. This pathway is more efficient in hypoxia, and this observation has led to the exploration of nitrate supplementation as a potential therapeutic strategy.[24]

4. Dietary nitrate and adipose tissue metabolism

Obesity is characterised by inappropriate accumulation of white adipose tissue (WAT) and an increase in adipocyte size. WAT stores energy as lipid which can then be released via lipolysis when required.[70] White adipocytes have a unilocular lipid droplet that takes up the vast majority of the cell and few mitochondria reflecting its low demand for energy.[71] In contrast, brown adipose tissue (BAT) is more metabolically active and utilises lipids as an energy source in a process termed non-shivering thermogenesis.[72] Brown adipocytes are small multilocular cells, characterised by a large number of mitochondria and synthesis of uncoupling protein 1 (UCP-1). In the mitochondria, UCP-1 acts to uncouple electron transport from ATP production, leading to the generation of heat, by increasing proton leak across the mitochondrial membrane.[73] Since thermogenesis is associated with an increase in lipolysis and fatty acid catabolism, via β-oxidation,
to supply fuel for the TCA cycle of the uncoupled mitochondria, it may have anti-obesity properties, restoring the defective energy balance in obese individuals. The adipose-specific transgenic expression of UCP-1 prevents obesity in mice [74], whilst the genetic ablation of BAT in mice results in obesity [75]. However, while thermogenesis appears to have therapeutic potential for the treatment of obesity, it is limited by the small amount of BAT present in adult humans, and is negatively correlated with age and adiposity [76].

Interestingly, a small number of cells within WAT were found to express UCP-1 upon cold exposure [77]. These cells were termed “beige” or “brite” cells and exhibit a gene expression profile distinct from either white or brown adipocytes [78]. The identification of beige adipocytes within WAT depots has increased interest in the utilisation of thermogenesis and increased energy expenditure to treat obesity. Beige cells have a low basal expression of UCP-1 but retain the capacity to greatly increase the expression of brown adipocyte-specific genes leading to increased respiration, mitochondrial biogenesis and fatty acid β-oxidation. The switch from a white adipocyte-like to a brown adipocyte-like phenotype is known as the browning response and has anti-obesity and anti-diabetic effects [74,79].

Numerous activators of the browning response have been identified, including cardiac natriuretic peptides, fibroblast growth factor 21, irisin and β-aminoisobutyric acid [80–84]. Recent studies have suggested that the anti-obesity effects of inorganic nitrate may function, in part, by inducing the browning response [55].

Dietary nitrate is known to increase the circulating concentration of cGMP in humans [85], while a diet deficient in nitrate decreases the steady-state concentration of cGMP in certain tissues [86]. cGMP has a profound effect on the regulation of energy metabolism in adipose tissue by activating adipocyte differentiation and lipolysis [87–89]. In 2013, Mitschke et al. identified cGMP as a small molecule capable of signalling via protein kinase G to stimulate the browning response in WAT [90]. In response to these previous studies Roberts et al. hypothesised that nitrate may induce the browning of WAT [55].

Roberts et al. demonstrated that inorganic nitrate increased brown adipocyte-specific gene expression, including UCP-1, in WAT both in vitro and in vivo [55]. The authors further characterised the brown adipocyte-like phenotype induced by nitrate using respirometry and stable isotope flux labelling analysis to confirm an increase in oxygen consumption and flux through the fatty acid β-oxidation pathway. Roberts et al. went on to elucidate the mechanisms underpinning the nitrate-induced browning effect (Fig. 2). Both the NO scavenger 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide and siRNA knockdown of XOR inhibited the nitrate-mediated induction of brown adipocyte-specific gene expression in primary adipocytes. The immediate reduction product of nitrate, nitrite, was also identified as an activator of the browning response. Using additional pharmacological inhibitors nitrate was found to signal downstream of NO via a pathway involving cGMP and protein kinase G. These findings lead the authors to conclude that nitrate functioned through the nitrate-nitrite-NO pathway and subsequent cGMP signalling to activate the browning response in adipose tissue, underlining the importance of NO in mediating the browning effects of nitrate.

As previously mentioned, the nitrate-nitrite-NO pathway acts to complement the oxygen-dependent NO synthases and utilises nitrate as a substrate in hypoxic conditions, thus providing NO in situations in which NO synthases are compromised [24]. Roberts et al. showed that both primary adipocytes and WAT from rats exposed to low oxygen levels had increased levels of XOR expression, which was further increased by nitrate treatment. In keeping with these concepts, the authors found that nitrate-induced browning was augmented by hypoxia (Fig. 2). This is particularly relevant given that the adipose tissue of obese mice and humans is characterised by hypoxia [91–93]. The oxygen concentrations utilised in this study mimicked oxygen levels found in obesity [93], thus nitrate may be an effective means of inducing the browning response in adipose tissue to treat obesity, T2DM and the metabolic syndrome.

Carlstrom et al.’s work highlighted how dietary nitrate can bring about a reduction in body weight and dyslipidaemia, while increasing glucose tolerance, on a phenotypic level [69]. The studies on the browning response show clearly how nitrate can readjust the energy imbalance in obesity, enhanced by the hypoxic conditions in the adipose of obese subjects. The catabolism of lipids through increased fatty acid β-oxidation provides a means to lower dyslipidaemia and alleviate aspects of lipid-induced insulin resistance in type 2 diabetics. Importantly, dietary nitrate appears to target multiple aspects of the metabolic syndrome.

5 Nitrate and hypertension

Dietary nitrate has a profound effect on hypertension, a major risk factor for CVD and another strand of the metabolic syndrome [94]. High blood pressure is defined as 140/90 mmHg [95]. Uncontrolled hypertension can increase the risk for CVD by nearly three times [96], while controlling hypertension reduces the risk of CVD [94,97–99]. Furthermore, according to the Centers for Disease Control and Prevention, approximately 67% of diabetic patients also have hypertension [100].

Endothelial dysfunction is a significant determinant of hypertension [101]. The loss of bioavailable NO has been implicated in endothelial dysfunction and the development of CVD [102,103]. Therefore, raising the levels of NO may have a beneficial impact on endothelial function and subsequent CVD. The potential for dietary nitrate to provide the much-needed supply of NO in these pathological situations has been examined in a number of recent studies in humans [104]. Ingestion of a single dose of beetroot juice, which contains a high concentration of nitrate, lowered both systolic and diastolic blood pressure [105], with the greatest effect
Figure 2. The effects of dietary inorganic nitrate on white adipose tissue. Dietary nitrate stimulates the browning response in hypoxic white adipose tissue. Nitrate is taken up from the blood by beige adipocytes where it triggers an increase in mitochondrial biogenesis, fatty acid β-oxidation and brown adipocyte-specific gene expression. The metabolic activity of the adipocytes is increased, raising the rate of thermogenesis. The mechanism by which nitrate activates browning relies on cGMP-PKG signalling, followed by increased expression of the transcriptional activator PGC-1α. PKG, protein kinase G.

after 3 h of nitrate consumption, concomitant with the highest concentrations of plasma nitrite and increased circulating cGMP concentrations. This lag may point towards nitrate as the causative agent and appears to resemble the time taken for nitrate to be reduced to nitrite, suggesting that the effects of dietary nitrate on blood pressure are mediated via the nitrate-nitrite-NO pathway. A study by Kenjale et al. further demonstrated that dietary nitrate reduces blood pressure in patients with peripheral artery disease [106], while nitrate has also been observed to lower blood pressure in hypertensive individuals [107]. A recent study by Kapil et al. investigated the long-term effects of daily doses of nitrate over a 4-week period [108]. Sustained dietary nitrate intake was found to reduce blood pressure, improve endothelial function and reduce arterial stiffness without any indication of tachyphylaxis over the 4-week period. Together, these studies highlight the potential of dietary nitrate as a therapeutic for patients with hypertension.

A number of recent studies have sought to identify the mechanisms underpinning the effect of dietary nitrate on hypertension. Wilcox postulated that during hypertension renal oxidative stress decreases NO bioavailability through the
production of reactive oxygen species, and suggested that the kidney may mediate the effects of dietary nitrate on blood pressure [109]. The kidneys regulate long-term maintenance of blood pressure via the release of vasoconstrictors and vasodilators, such as angiotensin II and NO, respectively [110]. Gao et al. demonstrated that dietary nitrate inhibited contractions triggered by angiotensin II in the renal microvasculature, via its XOR-catalyzed reduction to NO [111]. However, the effects of nitrite were shown to be partially independent of the NO-cGMP pathway, implying an alternative means by which nitrate, via NO, can bring about vasodilation [111]. This secondary mechanism was revealed to be an inhibitory action of NO on nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, as measured by superoxide production. Increases in angiotensin II activate NADPH oxidase, which in turn elevates levels of reactive oxygen species, and can lead to hypertension [112]. Concomitant treatment of arterioles with nitrate and apocynin, an NADPH oxidase inhibitor failed to attenuate contraction relative to nitrite treatment alone, suggesting that NO inhibits NADPH oxidase activity, an effect confirmed by assessing the inhibitory impact of nitrite on renal cortex NADPH oxidase activity [112]. Thus, nitrate may function via both the NO-cGMP pathway and via effects on the renal microvasculature by inhibiting NADPH oxidase to reduce blood pressure and exert beneficial effects on hypertension. Furthermore, Ashmore et al. recently observed that dietary nitrate may reduce blood pressure by inhibiting the production of erythropoietin [113]. Inorganic nitrate was found to trigger a time- and dose-dependent decrease in the hematocrit and circulating hemoglobin and erythropoietin concentrations. Nitrate also decreased hepatic expression of erythropoietin, which was mirrored by a fall in HIF1 target gene expression suggesting an increase in hepatic oxygen availability. A third of total erythropoietin production during hypoxia may be attributed to hepatic production [114]. Ashmore et al. propose that dietary nitrate may be effective as a therapeutic in any situation in which a reduction in hematocrit would be beneficial, such as polycythemia. Further, recent studies have indicated that a high hematocrit is associated with the incidence of hypertension and a pre-hypertensive state [115, 116]. Therefore, dietary nitrate could reduce blood pressure via a decrease in the expression of hepatic erythropoietin and a subsequent reduction in hematocrit. In summary, these studies together suggest that inorganic nitrate may reduce blood pressure through three distinct mechanisms (Fig. 3).

6 Dietary nitrate and the heart

As previously mentioned, nitrate is likely a key factor behind the cardioprotective effects of green leafy vegetables [16–18, [117]]. Hypoxia is known to alter cardiac energetics and decrease mitochondrial enzyme activities in the heart [118, 119]. Ashmore et al. suggest that dietary nitrate supplementation can protect the heart in hypoxic conditions by reversing hypoxia-induced effects on respiration rates, mitochondrial complex I levels and activity and protein carbonylation, a measure of oxidative stress [120].
interest was the observation that nitrate decreases arginase expression and activity, and increases L-arginine concentrations in the heart. It is postulated that this L-arginine could then be redirected from the arginase-dependent production of ornithine and urea to the production of NO. Arginase activity is associated with numerous cardiac pathologies [121] and hypoxia-induced alterations in energetics and mitochondrial dysfunction in the heart are key features of heart failure [122–124], thus dietary nitrate may have potential as a therapeutic to protect against numerous cardiac pathologies including heart failure.

7 Dietary nitrate, inflammation and iNOS

Obesity has long been associated with inflammation in insulin target tissues, especially adipose tissue depots, which is suggested to contribute to the pathology of the metabolic syndrome [125,126]. NO, produced by iNOS, is an important mediator of inflammation [127,128], and iNOS expression is increased in the skeletal muscle and adipose tissue of both genetic- and diet-induced models of obesity [129]. Furthermore, high fat diet-induced obese iNOS-null mice have improved insulin sensitivity compared to obese wild-type mice. Recent work by Yang et al. has shown inorganic nitrate can significantly reduce the mRNA levels of iNOS in activated macrophages [130]. While this study did not assess the effects of dietary nitrate on iNOS expression, the effects of nitrite were found to function through NO and require XOR, suggesting similar effects would be achieved with dietary nitrate. This paper highlights the potential for dietary nitrate to alleviate aspects of inflammation mediated by iNOS in the metabolic syndrome. However, much work is still required to elucidate the interaction between nitrate and inflammation in obesity, including a focus on the effects of dietary nitrate on the expression of iNOS in insulin-target tissues, such as skeletal muscle and adipose tissue.

8 Perspectives

Having initially been considered an inactive, then toxic and carcinogenic molecule, dietary inorganic nitrate is gradually being identified as a modulator of numerous aspects of the metabolic syndrome, with therapeutic potential against obesity, diabetes and hypertension. In the wake of recent work identifying the ability of nitrate to induce the browning response in adipose tissue and alter energy balance, lower blood pressure and decrease the haematocrit, the means by which nitrate protects against the metabolic syndrome are slowly being elucidated.

However, mechanistically, the picture remains incomplete. The identification of the nitrate-nitrite-NO pathway appeared to clarify that the bioactive effects of dietary nitrate were brought about by increasing bioavailable NO and downstream cGMP signalling. However, the recent discoveries that nitrate can inhibit the activity of both NADPH oxidase and arginase suggests the activity of nitrate is far more complex.

Furthermore, much of the in vivo work on dietary nitrate has been conducted in rodents, and there is a clear need to confirm these studies in humans to determine the therapeutic potential of dietary nitrate within the population. Nevertheless, it is evident that the use of dietary inorganic nitrate as a tool to tackle the metabolic syndrome has great potential. Dietary adjustment, with a focus on food groups high in nitrate, such as green leafy vegetables, provides an important starting point, but perhaps it is also time to reassess the attitudes to, and strict controls on, nitrate in our diets.

B.M. is supported by an MRC PhD studentship through MRC-Human Nutrition Research unit, Cambridge. L.D.R. is supported by the MRC-HNR Elsie Widdowson Fellowship. This work was supported by grants from the BBSRC (BB/H013539/2; bb/1000933/1), the Welcome Trust (093148/Z/10/Z), the British Heart Foundation and the MRC (Lipid Profiling and Signalling programme grant; number UD99999906).

The authors have declared no conflict of interest.

9 References

[1] Grosse, Y., Baan, R., Straif, K., Secretan, B. et al., Carcinogenicity of nitrate, nitrite, and cyanobacterial peptide toxins. Lancet Oncol. 2006, 7(8), 628–629.
[2] International Agency for Research on Cancer, IARC monographs on the evaluation of carcinogenic risks to humans. Ingested nitrate and nitrite, and cyanobacterial peptide toxins. IARC Monogr. Eval. Carcinog. Risks Hum. 2010, 94, 1–412.
[3] Buiatti, E., Palli, D., Decarli, A., Amadori, D. et al., A case-control study of gastric cancer and diet in Italy: II. Association with nutrients. Int. J. Cancer. 1990, 45(5), 896–901.
[4] Mayne, S. T., Risch, H. A., Dubrow, R., Chow, W. H. et al., Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2001, 10(10), 1055–1062.
[5] Toxicology and carcinogenesis studies of sodium nitrite (CAS NO. 7632-00-0) in F344/N rats and B6C3F1 mice (drinking water studies). Natl. Toxicol. Program Tech. Rep. Ser. 2001, 495, 7–273.
[6] Greenblatt, M., Mirvish, S., So, B. T., Nitrosamine studies: induction of lung adenomas by concurrent administration of sodium nitrite and secondary amines in Swiss mice. J. Natl. Cancer Inst. 1971, 46, 1029–1034.
[7] Lijinsky, W., Induction of tumours in rats by feeding nitrosatable amines together with sodium nitrite. Food Chem. Toxicol. 1984, 22, 715–720.
[8] Swann, P. F., Magee, P. N., Nitrosamine-induced carcinogenesis. The alkylation of nucleic acids of the rat by N-methyl-N-nitrosourea, dimethylnitrosamine, dimethyl sulphate and methyl methanesulphonate. Biochem. J. 1968, 110, 39–47.
Lundberg, J. O., Carlström, M., Larsen, F. J., Weitzberg, E., Roles of dietary inorganic nitrate in cardiovascular health and disease. Cardiovasc. Res. 2011, 89(3), 525–532.

Lundberg, J. O., Weitzberg, E., Gladwin, M. T., The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 2008, 7, 156–167.

Antosova, M., Nitric oxide—important messenger in human body. Open J. Mol. Integr. Physiol. 2012, 02, 98–106.

Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E. et al., Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 1987, 84, 9265–9269.

Palmer, R. M., Ferrige, A. G., Moncada, S., Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327, 524–526.

Loscalzo, J., Welch, G., Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis. 1995, 38, 87–104.

Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E. et al., Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007, 8, 766–775.

Bogdan, C., Nitric oxide and the immune response. Nat. Immunol. 2001, 2, 907–916.

Andrew, P., Enzymatic function of nitric oxide synthases, Cardiovasc. Res. 1999, 43(3), 521–531.

Griffith, O. W., Stuehr, D. J., Nitric oxide synthases: properties and catalytic mechanism. Annu. Rev. Physiol. 1995, 57, 707–736.

Bartholomew, B., Hill, M. J., The pharmacology of dietary nitrate and the origin of urinary nitrate. Food Chem. Toxicol. 1984, 22(10), 789–795.

Spiegelhalder, B., Eisenbrand, G., Preussmann, R., Influence of dietary nitrate on nitrite content of human saliva: possible relevance to in vivo formation of N-nitrosocompounds. Food Cosmet. Toxicol. 1976, 14(6), 545–548.

Duncan, C., Dougal, H., Johnston, P., Green, S. et al., Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate, Nat. Med. 1995, 1(6), 546–551.

Benjamin, N., O’Driscoll, F., Dougal, H., Duncan, C. et al., Stomach NO synthesis. Nature 1994, 368(6471), 502.

Peri, L., Pietraforte, D., Scorza, G., Napoliollo, A. et al., Apples increase nitric oxide production by human saliva at the acidic pH of the stomach: a new biological function for polyphenols with a catechol group? Free Radic. Biol. Med. 2005, 39(5), 668–681.

Gago, B., Lundberg, J. O., Barbosa, R. M., Laranjinha, J., Red wine-dependent reduction of nitrite to nitric oxide in the stomach. Free Radic. Biol. Med. 2007, 43(9), 1233–1242.

Jansson, E. A., Huang, L., Malkey, R., Govoni, M. et al., A mammalian functional nitrate reductase that regulates nitrite and nitric oxide homeostasis. Nat. Chem. Biol. 2008, 4(7), 411–417.

Ward, F. W., Coates, M. E., Cole, C. B., Fuller, R., Effect of dietary fats on endogenous formation of N-nitrosamines from nitrate in germ-free and conventional rats and rats.
harbouring a human flora. Food Addit. Contam. 1990, 7, 597–604.

[41] Alifkulov, Z. A., L’vov, N. P., Kretovich, V. L., Nitrate and nitrite reductase activity of milk xanthine oxidase. Biochimiiä 1980, 45, 1714–1718.

[42] Millar, T. M., Stevens, C. R., Benjamin, N., Eisenthal, R. et al., Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett. 1998, 427, 225–228.

[43] Li, H., Samouilov, A., Liu, X., Zweier, J. L., Characterization of the magnitude, kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite, nitric oxide generation in anoxic tissues. Biochemistry 2003, 42, 1150–1159.

[44] Govoni, M., Jansson, E. A., Weitzberg, E., Lundberg, J. O., The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. Nitric Oxide 2008, 19, 333–337.

[45] Cosby, K., Partovi, K. S., Crawford, J. H., Patel, R. P. et al., Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat. Med. 2003, 9, 1498–1505.

[46] Shiva, S., Huang, Z., Grubina, R., Sun, J. et al., Deoxymyglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ. Res. 2007, 100, 5, 654–661.

[47] Rassaf, T., Preik, M., Kleinbongard, P., Lauer, T. et al., Evidence for in vivo transport of bioactive nitric oxide in human plasma. J. Clin. Invest. 2002, 109, 1241–1248.

[48] Totzeck, M., Hendgen-Cotta, U. B., Luedike, P., Berenbrink, M. et al., Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation. Circulation 2012, 126, 325–334.

[49] Nohl, H., Staniek, K., Sobhian, B., Bahrami, S. et al., Mitochondria recycle nitrite back to the bioregulator nitric monoxide. Acta Biochim. Pol. 2000, 47, 913–921.

[50] Castello, P. R., David, P. S., McClure, T., Crook, Z. et al., Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling in eukaryotes. Cell Metab. 2006, 3, 277–287.

[51] Kozlov, A. V., Staniek, K., Nohl, H., Nitrite reductase activity is a novel function of mammalian mitochondria. FEBS Lett. 1999, 454, 127–130.

[52] Kelm, M., Nitric oxide metabolism and breakdown. Biochim. Biophys. Acta - Bioenerg. 1999, 1411, 273–289.

[53] Maher, A. R., Millsom, A. B., Gunaruwan, P., Abozguia, K. et al., Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. Circulation 2008, 117, 670–677.

[54] Gladwin, M. T., Evidence mounts that nitrite contributes to hypoxic vasodilation in the human circulation. Circulation 2008, 117, 594–597.

[55] Roberts, L. D., Ashmore, T., Kotwica, A. O., Murfitt, S. A. et al., Inorganic nitrite promotes the browning of white adipose tissue through the nitrate-nitrite-nitric oxide pathway. Diabetes 2014, 64, 471–484.

[56] Huang, L., Borniquel, S., Lundberg, J. O., Enhanced xanthine oxidoreductase expression and tissue nitrate reduction in germ free mice. Nitric Oxide 2010, 22, 191–195.

[57] Huang, P. L., A comprehensive definition for metabolic syndrome. Dis. Model. Mech. 2009, 2, 231–237.

[58] Eckel, R. H., Grundy, S. M., Zimme, P. Z., The metabolic syndrome. Lancet 2005, 365, 1415–1428.

[59] Daneai, G., Finucane, M. M., Lu, Y., Singh, G. M. et al., National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378, 31–40.

[60] Virtue, S. and Vidal-Puig, A., Adipose tissue expandability, lipotoxicity and the metabolic syndrome—an allostatic perspective. Biochim. Biophys. Acta 2010, 1801, 338–349.

[61] Randle, P. J., Garland, P. B., Hales, C. N., Newsholme, E. A., The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1, 785–789.

[62] Griffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K. et al., Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999, 48, 1270–1274.

[63] Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E. et al., Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 1999, 103, 253–259.

[64] Huang, P. L., eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol. Metab. 2009, 20, 295–302.

[65] Monti, L. D., Barlassina, C., Citterio, L., Galluccio, E. et al., Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes 2003, 52, 1270–1275.

[66] Siervo, M., Jackson, Bluck, L. J. C., In-vivo nitric oxide synthesis is reduced in obese patients with metabolic syndrome: application of a novel stable isotopic method. J. Hypertens. 2011, 29, 1515–1527.

[67] Cook, S., Hugli, O., Egli, M., Vollenweider, P. et al., Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med. Wkly. 2003, 133, 360–363.

[68] Duplain, H., Burcelin, R., Sartori, C., Cook, S. et al., Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001, 104, 342–345.

[69] Carlström, M., Larsen, F. J., Nyström, T., Hezel, M. et al., Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice. Proc. Natl. Acad. Sci. USA 2010, 107, 17716–17720.

[70] Duncan, R. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E. et al., Regulation of lipolysis in adipocytes. Annu. Rev. Nutr. 2007, 27, 79–101.

[71] Saely, C. H., Geiger, K., Drexel, H., Brown versus white adipose tissue: a mini-review. Gerontology 2012, 58, 15–23.
[72] Cannon, B., Nedergaard, J., Brown adipose tissue: function and physiological significance. *Physiol. Rev.* 2004, 84, 277–359.

[73] Fedorenko, A., Lishko, P. V., Kirichok, Y., Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria. *Cell 2012*, 151, 400–413.

[74] Kopecky, J., Clarke, G., Enerbäck, S., Spiegelman, B. et al., Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. *J. Clin. Invest.* 1995, 96, 2914–2923.

[75] Lowell, B. B., S-Susulic, V., Hamann, A., Lawitts, J. A. et al., Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. *Nature 1993*, 366, 740–742.

[76] Pfannenberg, C., Werner, M. K., Ripkens, S., Stef, I. et al., Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. *Diabetes 2010*, 59, 1789–1793.

[77] Young, P., Arch, J. R., Ashwell, M., Brown adipose tissue in the parametrial fat pad of the mouse. *FEBS Lett.* 1984, 167, 10–14.

[78] Wu, J., Boström, P., Sparks, L. M., Ye, L. et al., Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell 2012*, 150, 366–376.

[79] Ghorbani, M., Claus, T. H., Himms-Hagen, J., Hypertrophy of brown adipocytes in brown and white adipose tissues in rats treated with a beta3-adrenoceptor agonist. *Biochem. Pharmacol.* 1997, 54, 121–131.

[80] Bordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G. et al., Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. *J. Clin. Invest.* 2012, 122, 1022–1036.

[81] Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C. et al., FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. *Genes Dev.* 2012, 26, 271–281.

[82] Boström, P., Wu, J., Jedrychowski, M. P., Korde, A. et al., A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature 2012*, 481, 463–468.

[83] Roberts, L. D., Boström, P., O’ Sullivan, J. F., Schinzel, R. T. et al., β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors. *Cell Metab.* 2014, 19, 96–108.

[84] Wu, J., Cohen, P., Spiegelman, B. M., Adaptive thermogenesis in adipocytes: is beige the new brown? *Genes Dev.* 2013, 27, 234–250.

[85] Kapil, V., Milsom, A. B., Okorie, M., Maleki-Toyserkani, S. et al., Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. *Hypertension 2010*, 56, 274–281.

[86] Bryan, N. S., Fernandez, B. O., Bauer, S. M., Garcia-Saura, M. F. et al., Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. *Nat. Chem. Biol.* 2005, 1, 290–297.

[87] Katayama, T., Garbers, D. L., Albanesi, J. P., CNP/GC-B system: a new regulator of adipogenesis. *Peptides 2010*, 31, 1906–1911.

[88] Nishikimi, T., Iemura-Inaba, C., Akimoto, K., Ishikawa, K. et al., Stimulatory and Inhibitory regulation of lipolysis by the NPR-A/cGMP/PKG and NPR-C/G(i) pathways in rat cultured adipocytes. *Regul. Pept.* 2009, 153, 56–63.

[89] Zhang, X., Ji, J., Yan, G., Wu, J. et al., Sildenafil promotes adipogenesis through a PKG pathway. *Biochem. Biophys. Res. Commun. 2010*, 396, 1054–1059.

[90] Mitschke, M. M., Hoffmann, L. S., Gnad, T., Scholz, D. et al., Increased cGMP promotes healthy expansion and browning of white adipose tissue. *FASEB J.* 2013, 27, 1621–1630.

[91] Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y. et al., Adipose tissue hypoxia in obesity and its impact on adipocyte-toxine dysregulation. *Diabetes 2007*, 56, 901–911.

[92] Kabon, B., Nagele, A., Reddy, D., Eagon, C. et al., Obesity decreases perioperative tissue oxygenation. *Anesthesiology 2004*, 100, 274–280.

[93] Ye, J., Gao, Z., Yin, J., He, Q., Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. *Am. J. Physiol. Endocrinol. Metab.* 2007, 293, E1118–E1128.

[94] Sowers, J. R., Epstein, M., Frohlich, E. D., Diabetes, hypertension, and cardiovascular disease: an update. *Hypertension 2001*, 37, 1053–1059.

[95] Krause, T., Lovibond, K., Caulfield, M., McCormack, T. et al., Management of hypertension: summary of NICE guidance. *BMJ 2011*, 342, d4891.

[96] Wang, W., Lee, E. T., Fabsitz, R. R., Devereux, R. et al., A longitudinal study of hypertension risk factors and their relation to cardiovascular disease: the Strong Heart Study. *Hypertension 2006*, 47, 403–409.

[97] Collins, R., Peto, R., MacMahon, S., Hebert, P. et al., Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. *Lancet 1990*, 335, 827–838.

[98] Hansson, L., Lindholm, L. H., Niskanen, L., Larne, J. et al., Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet 1999*, 353, 611–616.

[99] Yusuf, S., Sleight, P., Pogue, J., Bosch, J. et al., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N. Engl. J. Med.* 2000, 342, 145–153.

[100] Centers for Disease Control and Prevention, *National Diabetes Fact Sheet*, 2011.

[101] Puddu, P., Puddu, G. M., Zaca, F., Muscari, A., Endothelial dysfunction in hypertension. *Acta Cardiol.* 2000, 55, 221–232.
[102] Cai, H., Harrison, D. G., Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. *Circ. Res.* 2000, 87, 840–844.

[103] Cannon, R. O., Role of nitric oxide in cardiovascular disease: focus on the endothelium. *Clin. Chem.* 1998, 44, 1809–1819.

[104] Hobbs, D. A., George, T. W., Lovegrove, J. A., The effects of dietary nitrate on blood pressure and endothelial function: a review of human intervention studies. *Nutr. Res. Rev.* 2013, 26, 210–222.

[105] Webb, A. J., Patel, N., Loukogeorgakis, S., Okorie, M. et al., Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. *Hypertension* 2008, 51, 784–790.

[106] Kenjale, A. A., Ham, K. L., Stabler, T., Robbins, J. L. et al., Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. *J. Appl. Physiol.* 2011, 110, 1582–1591.

[107] Ghosh, S. M., Kapil, V., Fuentes-Calvo, I., Bubb, K. J. et al., Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. *Hypertension* 2013, 61, 1091–1102.

[108] Kapil, V., Khambata, R. S., Robertson, A., Caulfield, M. J. et al., Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. *Hypertension* 2015, 65, 320–327.

[109] Wilcox, C. S., Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2005, 289, R913–R935.

[110] Patzak, A., Persson, A. E. G., Angiotensin II-nitric oxide interaction in the kidney. *Curr. Opin. Nephrol. Hypertens.* 2007, 16, 46–51.

[111] Gao, X., Yang, T., Liu, M., Peleli, M. et al., NADPH oxidase in the renal microvasculature is a primary target for blood pressure-lowering effects by inorganic nitrate and nitrite. *Hypertension* 2014, 65, 161–170.

[112] Datla, S. R., Griendling, K. K., Reactive oxygen species, NADPH oxidases, and hypertension. *Hypertension* 2010, 56, 325–330.

[113] Ashmore, T., Fernandez, B. O., Evans, C. E., Huang, Y. et al., Suppression of erythropoiesis by dietary nitrate. *FASEB J.* 2014, 29, 1102–1112.

[114] Eckardt, K. U., Ratcliffe, P. J., Tan, C. C., Bauer, C. et al., Age-dependent expression of the erythropoietin gene in rat liver and kidneys. *J. Clin. Invest.* 1992, 89, 753–760.

[115] Jae, S. Y., Kurl, S., Laukkonen, J. A., Heffernan, K. S. et al., Higher blood hematocrit predicts hypertension in men. *J. Hypertens.* 2014, 32, 245–250.

[116] Liu, X., Liang, J., Qiu, Q., Zhu, Y. et al., Association of hematocrit and pre-hypertension among Chinese adults: the CRC Study. *Cell Biochem. Biophys.* 2015, 71, 1123–1128.

[117] Joshiyura, K. J., Hu, F. B., Manson, J. E., Stampfer, M. J. et al., The effect of fruit and vegetable intake on risk for coronary heart disease. *Ann. Intern. Med.* 2001, 134, 1106–1114.

[118] Holloway, C. J., Montgomery, H. E., Murray, A. J., Cochlin, L. E. et al., Cardiac response to hypobaric hypoxia: persistent changes in cardiac mass, function, and energy metabolism after a trek to Mt. Everest base camp. *FASEB J.* 2011, 25, 792–796.

[119] Heather, L. C., Cole, M. A., Tan, J.-J., Ambrose, L. J. A. et al., Metabolic adaptation to chronic hypoxia in cardiac mitochondria. *Basic Res. Cardiol.* 2012, 107, 268–280.

[120] Ashmore, T., Fernandez, B. O., Branco-Price, C., West, J. A. et al., Dietary nitrate increases arginine availability and protects mitochondrial complex I and energetics in the hypoxic rat heart. *J. Physiol.* 2014, 592, 4715–4731.

[121] Pernow, J., Jung, C., Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? *Cardiovasc. Res.* 2013, 98, 334–343.

[122] William, C., Maxwell, P. H., Nichols, L., Lygate, C. et al., HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. *J. Mol. Cell. Cardiol.* 2006, 41, 68–77.

[123] Murray, A. J., Lygate, C. A., Cole, M. A., Carr, C. A. et al., Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart. *Cardiovasc. Res.* 2006, 71, 149–157.

[124] Murray, A. J., Cole, M. A., Lygate, C. A., Carr, C. A. et al., Increased mitochondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the chronically infarcted rat heart. *J. Mol. Cell. Cardiol.* 2008, 44, 694–700.

[125] Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J. et al., Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. *Diabetes Res. Clin. Pract.* 2014, 105, 141–150.

[126] Monteiro, R., Azevedo, I., Chronic inflammation in obesity and the metabolic syndrome. *Mediators Inflamm.* 2010, 2010, doi: 10.1155/2010/289645.

[127] Zamora, R., Vodovotz, Y., Billiar, T. R., Inducible nitric oxide synthase protects against obesity-linked insulin resistance in type 2 diabetes. *Diabetes Res. Clin. Pract.* 2010, 90, 347–373.

[128] Sharma, J. N., Al-Omran, A., Parvathy, S. S., Role of nitric oxide in inflammatory diseases. *Inflammopharmacology* 2008, 15, 252–259.

[129] Perreault, M., Marette, A., Targeted disruption of inducible nitric oxide synthase and inflammatory diseases. *Mol. Med.* 2000, 6, 347–373.

[130] Yang, T., Peleli, M., Zollbrecht, C., Giulietti, A. et al., Inorganic nitrite attenuates NADPH oxidase-derived superoxide generation in activated macrophages via a nitric oxide-dependent mechanism. *Free Radic. Biol. Med.* 2015, 83, 159–166.